ReviewGlobal health & medicine2020
Interpretation of guidelines for the diagnosis and treatment of primary liver cancer (2019 edition) in China.
Review in Global health & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Effect of Huaier Granules combined with transarterial chemoembolization on recurrence and survival in postoperative hepatocellular carcinoma patients with microvascular invasion.American journal of translational research · 2026Article
- Predicting venous thromboembolism risk after TACE in hepatocellular carcinoma: a logistic model and nursing protocol development.American journal of translational research · 2026Article
- Effects of Lenvatinib combined with immune checkpoint inhibitors on efficacy, immune function and prognosis in patients with primary liver cancer.Pakistan journal of medical sciences · 2025Article
- Debates and progress in the management of intermediate-stage (BCLC stage B) hepatocellular carcinoma.iLIVER · 2025Review
- Hepatic artery infusion chemotherapy combined with lenvatinib and PD-1 inhibitors in the treatment of intermediate and advanced unresectable hepatocellular carcinoma.Oncology letters · 2025Article
- Clinical Implications and Novel Insights into Adolescent Primary Liver Cancer: A Nightmare for Adolescents?Journal of hepatocellular carcinoma · 2025Article
- Postoperative subphenotypes modified the hepatoma arterial-embolization prognostic score: A novel smHAP-II nomogram.Journal of Cancer · 2024Article
- The impact of drug-eluting bead (vs. conventional) transarterial chemoembolization on hepatic fibrosis in treating intermediate or advanced hepatocellular carcinoma.Cancer biology & therapy · 2023Article
- Baicalin inhibits the replication of the hepatitis B virus by targeting TRIM25.Journal of traditional and complementary medicine · 2023Article
- Development of preoperative and postoperative machine learning models to predict the recurrence of huge hepatocellular carcinoma following surgical resection.Oncology letters · 2023Article
- Comparison of preoperative ultrasound and MRI in the diagnosis of microvascular invasion in hepatocellular carcinoma.Functional & integrative genomics · 2023Article
- Article
- Comparison of the clinical efficacy of donafinil and lenvatinib in the treatment of intermediate and advanced hepatocellular carcinoma.American journal of translational research · 2023Article
- Bioinformatics screening the novel and promising targets of curcumin in hepatocellular carcinoma chemotherapy and prognosis.BMC complementary medicine and therapies · 2022Article
- Effectiveness and Safety of Anlotinib with or without PD-1 Blockades in the Treatment of Patients with Advanced Primary Hepatocellular Carcinoma: A Retrospective, Real-World Study in China.Drug design, development and therapy · 2022Article
- A retrospective study of enteral nutrition on immune and inflammatory factors after liver cancer surgery.Medicine · 2021Article
- Recent update on comprehensive therapy for advanced hepatocellular carcinoma.World journal of gastrointestinal oncology · 2021Review
- Classification of hepatic venous tumor thrombus in hepatocellular carcinoma: should it describe tumor status or predict patient survival?Hepatobiliary surgery and nutrition · 2021Article
- Inhibition of SUMO2/3 antagonizes isoflurane-induced cancer-promoting effect in hepatocellular carcinoma Hep3B cells.Oncology letters · 2021Article
- Circulating Tumor Cell Is a Clinical Indicator of Pretransplant Radiofrequency Ablation for Patients with Hepatocellular Carcinoma.Journal of oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary liver cancer (PLC) is currently the fourth most common malignancy and accounts for the second most cancer-related deaths in China. Since 2017, a great deal of high-level evidence, and particularly evidence based on Chinese studies and practice, has emerged in terms of diagnosis, staging, and treatment. A new version of the guidelines for the management of PLC specifying the diagnosis and treatment of PLC (2019 edition) has recently been published. The guidelines feature major changes in the techniques for early diagnosis, the combination of surgery, local therapy, and systemic treatment, and the use of traditional Chinese medicine. The guidelines need to be further implemented in clinical practice to demonstrate their validity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.